Angiocrine Bioscience Company
Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
Technology:
Bioengineering
Industry:
Cell Therapy, Private
Headquarters:
New York, New York, United States
Founded Date:
2012-01-01
Employees Number:
11-50
Funding Status:
Private Equity
Investors Number:
1
Total Funding:
77121795
Estimated Revenue:
$1M to $10M
Last Funding Date:
2022-12-19
Last Funding Type:
Grant
Register and Claim Ownership